Literature DB >> 26268855

Incidence and Predictors of Abnormal Anal Cytology Findings Among HIV-Infected Adults Receiving Contemporary Antiretroviral Therapy.

Lois J Conley1, Timothy J Bush1, Teresa M Darragh2, Joel M Palefsky2, Elizabeth R Unger2, Pragna Patel1, Martin Steinau2, E Milu Kojic3, Harold Martin4, E Turner Overton5, Susan Cu-Uvin3, John Hammer6, Keith Henry7, Kathleen Wood8, John T Brooks1.   

Abstract

BACKGROUND: Anal cancer rates are higher for human immunodeficiency virus (HIV)-infected adults than for uninfected adults. Limited published data exist characterizing the incidence of precursor lesions detected by anal cytology.
METHODS: The Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy was a prospective cohort of 700 HIV-infected participants in 4 US cities. At baseline and annually thereafter, each participant completed a behavioral questionnaire, and healthcare professionals collected anorectal swabs for cytologic examination and human papillomavirus (HPV) detection and genotyping.
RESULTS: Among 243 participants with negative baseline results of anal cytology, 37% developed abnormal cytology findings (incidence rate, 13.9 cases/100 person-years of follow-up; 95% confidence interval [CI], 11.3-16.9) over a median follow-up duration of 2.1 years. Rates among men having sex with men, among women, and among men having sex with women were 17.9 cases/person-years of follow-up (95% CI, 13.9-22.7), 9.4 cases/person-years of follow-up (95% CI, 5.6-14.9), and 8.9 cases/person-years of follow-up (95% CI, 4.8-15.6), respectively. In multivariable analysis, the number of persistent high-risk HPV types (adjusted hazard ratio [aHR], 1.17; 95% CI, 1.01-1.36), persistent high-risk HPV types except 16 or 18 (aHR, 2.46; 95% CI, 1.31-4.60), and persistent types 16 or 18 (aHR, 3.90; 95% CI, 1.78-8.54) remained associated with incident abnormalities.
CONCLUSIONS: The incidence of abnormal anal cytology findings was high and more likely to develop among persons with persistent high-risk HPV. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  HIV; HPV; abnormal anal cytology; incidence; persistence

Mesh:

Substances:

Year:  2015        PMID: 26268855      PMCID: PMC6103209          DOI: 10.1093/infdis/jiv408

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States.

Authors:  L Conley; T Bush; T M Darragh; J M Palefsky; E R Unger; P Patel; E M Kojic; S Cu-Uvin; H Martin; E T Overton; J Hammer; K Henry; C Vellozzi; K Wood; J T Brooks
Journal:  J Infect Dis       Date:  2010-10-06       Impact factor: 5.226

2.  High prevalence and incidence of high-grade anal intraepithelial neoplasia among young Thai men who have sex with men with and without HIV.

Authors:  Nittaya Phanuphak; Nipat Teeratakulpisarn; Surang Triratanachat; Somboon Keelawat; Tippawan Pankam; Stephen J Kerr; Amornrat Deesua; Patou Tantbirojn; Saranya Numto; Praphan Phanuphak; Joel M Palefsky; Jintanat Ananworanich
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

3.  Prevalence of abnormal anal cytology and high-grade squamous intraepithelial lesions among a cohort of HIV-infected men who have sex with men.

Authors:  Elena Sendagorta; Pedro Herranz; Hector Guadalajara; Jose Ignacio Bernardino; Jose María Viguer; María José Beato; Damian García-Olmo; Jose María Peña
Journal:  Dis Colon Rectum       Date:  2014-04       Impact factor: 4.585

Review 4.  Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem.

Authors:  J M Palefsky
Journal:  AIDS       Date:  1994-03       Impact factor: 4.177

5.  Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy.

Authors:  Catherine Diamond; Thomas H Taylor; Tabatha Aboumrad; Deborah Bringman; Hoda Anton-Culver
Journal:  Sex Transm Dis       Date:  2005-05       Impact factor: 2.830

6.  Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors.

Authors:  Margaret M Madeleine; Tarja Anttila; Stephen M Schwartz; Pekka Saikku; Maija Leinonen; Joseph J Carter; Michelle Wurscher; Lisa G Johnson; Denise A Galloway; Janet R Daling
Journal:  Int J Cancer       Date:  2007-02-01       Impact factor: 7.396

Review 7.  Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions.

Authors:  Brooke E Hoots; Joel M Palefsky; Jeanne M Pimenta; Jennifer S Smith
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

8.  Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women.

Authors:  Amanda J Durante; Ann B Williams; Maria Da Costa; Teresa M Darragh; Kaveh Khoshnood; Joel M Palefsky
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-07       Impact factor: 4.254

9.  Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men.

Authors:  Ina U Park; Joel M Palefsky
Journal:  Curr Infect Dis Rep       Date:  2010-02-24       Impact factor: 3.725

10.  Pattern of cancer risk in persons with AIDS in Italy in the HAART era.

Authors:  L Dal Maso; J Polesel; D Serraino; M Lise; P Piselli; F Falcini; A Russo; T Intrieri; M Vercelli; P Zambon; G Tagliabue; R Zanetti; M Federico; R M Limina; L Mangone; V De Lisi; F Stracci; S Ferretti; S Piffer; M Budroni; A Donato; A Giacomin; F Bellù; M Fusco; A Madeddu; S Vitarelli; R Tessandori; R Tumino; B Suligoi; S Franceschi
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

View more
  1 in total

1.  HIV & Hepatitis in the Americas 28-30 April 2016, Mexico City, Mexico.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-04-28       Impact factor: 5.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.